Welcome to Inke's Product Portfolio page

Explore our extensive range of APIs and discover how Inke is dedicated to advancing pharmaceutical innovation and improving patient outcomes.

Inke specializes in the development and manufacturing of active pharmaceutical ingredients, with a primary focus on respiratory inhalation therapies. In addition to our expertise in respiratory APIs, we also produce high-quality APIs for various other therapeutic areas, ensuring comprehensive solutions to meet diverse medical needs.

Our commitment to quality and innovation is evident in every product line, enabling us to provide comprehensive solutions tailored to the evolving needs of the pharmaceutical industry. Below, you will find a detailed list of our products, highlighting our respiratory APIs alongside our full product portfolio, demonstrating our dedication to excellence across all therapeutic areas

API Indication Micronised / PSD CEP EU DMF US DMF JP DMF KR DMF CN DMF RU DMF
Aclidinium bromide COPD
Arformoterol tartrate (A) COPD
Arformoterol tartrate (D) p COPD
Formoterol fumarate

dihydrate

Asthma and COPD
Glycopyrrolate bromide p COPD
Indacaterol acetate Asthma
Indacaterol maleate p Asthma and COPD
Montelukast sodium p Asthma, allergic & seasonal rhinitis
Olodaterol HCl p COPD
Revefenacin trihydrate COPD
Salmeterol xinafoate p Asthma and COPD
Tiotropium bromide

monohydrate

COPD
Umeclidinium bromide COPD
Vilanterol trifenatate Asthma and COPD

Product Portfolio

Explore our product list below, featuring our extensive range of high-quality APIs across all therapeutic areas. This includes our specialized respiratory APIs as well as APIs for various other medical needs, showcasing our commitment to delivering excellence in pharmaceutical manufacturing.

THERAPEUTIC AREA PRODUCT INDICATION API MICRONIZED CEP / DMF
Antiallergics Loratadine P Allergy JP DMF
Antiasthmatics, COPD and respiratory diseases Aclidinium bromide COPD EU-US DMF
Arformoterol tartrateP polymorph A and D COPD US-CN–KR DMF
Formoterol fumarate dihydrate Asthma and COPD CEP/US-CN-JP-KR DMF
Glycopyrronium bromideP COPD CEP/US-CN-KR DMF
Indacaterol maleateP COPD EU-US-CN-KR DMF
Montelukast sodium Asthma, allergic & seasonal rhinitis EU-JP DMF
Olodaterol HClP COPD EU-US-CN DMF
Revefenacin trihydrate COPD EU-US-CN DMF
Salmeterol xinafoateP Asthma and COPD CEP/ US-CN-KR DMF
Tiotropium bromide monohydrate COPD CEP/US-CN-RU DMF
Umeclidinium bromide COPD EU-US-CN DMF
Vilanterol trifenatate Asthma and COPD EU-US DMF
Antiemetics Aprepitant Emesis CEP*/US DMF
Granisetron baseP Emesis US DMF
Granisetron HClP Emesis CEP/US-JP-KR DMF
Ondansetron baseP Emesis EU-US DMF
Ondansetron HClP Emesis CEP/US DMF
Antihipertensive CarvedilolP Hypertension, angina, heart failure JP DMF
Clevidipine butyrateP Hypertension EU-US-CN DMF
Enalapril maleateP Hypertension CEP/KR DMF
Imidapril Hypertension EU DMF
Nitrendipine Hypertension CEP/DMF
Antimigrainics Eletriptan hydrobromideP Migraine JP DMF
Rizatriptan benzoateP Migraine EU-US DMF
ZolmitriptanP Migraine EU-US DMF
Antiparkinson Tetrabenazine Huntington’s disease chorea and Tardive dyskinesia EU-US DMF
Antipsychotics Asenapine maleateP Schizophrenia and acute mania JP DMF
OlanzapineP Schizophrenia, psychosis EU-US-KR DMF
Quetiapine hemifumarateP Schizophrenia, psychosis JP-KR DMF
RisperidoneP Schizophrenia, psychosis CEP/US-CN-KR DMF
Antithrombotics Prasugrel baseP Prophylaxis & therapy of thrombosis EU DMF
Rivaroxaban Thrombosis. Stroke CEP /US DMF
Spasmolytic Otilonium bromide Irritable bowel syndrome EU DMF

Pipeline

Our dedication to innovation is reflected in our robust pipeline of products under development. These upcoming APIs are designed to address unmet medical needs and provide new therapeutic options for various health conditions.

THERAPEUTIC AREA PRODUCT INDICATION SAMPLES TECHNICAL PACKAGE VALIDATION BATCH DMF
Antiasthmatics, COPD and respiratory diseases Ensifentrine COPD Q4 2024 Q2 2025 Q3 2025 Q1 2026
Indacaterol acetate Asthma Q4 2024 Q3 2025
Tanimilast COPD TBC
Antiparkinson Benserazide HCl Parkinson’s disease Pending
Rotigotine Parkinson’s disease Q4 2024 Q1 2025 Q4 2025
Other disorders Daprodustat Anemia due to CKD Q4 2024 Q4 2024 Q2 2025 Q4 2025
Daridorexant Insomnia Q3 – Q4 2025 Q4 2025 Q4 2025 – Q1 2026 Q3 – Q4 2026
Mavacamten Cardiomyopathy Q4 2024 Q4 2024 Q2 2025
Momelotinib Myelofibrosis TBC
Olanzapine pamoate Schizophrenia, psychosis TBC
Prasugrel HCl Prophylaxis & therapy of thrombosis Q2 2024 Pending Pending
Solriamfetol HCl Narcolepsy Q1 2025 Q2 2025 Pending
Tafamidis meglumine Transthyretin amyloidosis Q1 – Q2 2025

CEP = Products with Certificate of Suitability
P = Patent applications/granted patents owned by Inke
* = submitted (under evaluation)

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

Inke © Confidential

To access the downloadable PDF, please complete the form provided below.

Thanks for your select. We will contact you shortly.
Your email could not be sent. Please try again.
Validation with errors. Please try again.